 |
424 Diseases |  |
809 Trials |
|
809 Trials |  |
14393 News |  |
| «12...149150151152153154155156157158159...235236» |
- | Trial primary completion date, Metastases: Induction Chemotherapy for Locally Advanced Esophageal Cancer (clinicaltrials.gov) - Jul 20, 2020
P2, N=40, Recruiting, Sponsor: University of Rochester
Trial primary completion date: Jun 2020 --> Jun 2021
- ||| numidargistat (INCB001158) / Calithera
Enrollment closed, Enrollment change, Combination therapy, Metastases: A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors (clinicaltrials.gov) - Jul 20, 2020
P1/2, N=149, Active, not recruiting, Sponsor: Incyte Corporation
Trial primary completion date: Jun 2020 --> Jun 2021 N=249 --> 149 | Recruiting --> Active, not recruiting
- Onivyde (nanoliposomal irinotecan) / Servier, Ipsen, Takeda, PharmaEngine
[VIRTUAL] NANOLIPOSOMAL IRINOTECAN WITH FLUOROURACIL AND FOLINIC ACID IN METASTATIC PANCREATIC CANCER AFTER PREVIOUS GEMCITABINE-BASED THERAPY: A REAL WORLD EXPERIENCE (Poster Exhibition) - Jul 19, 2020 - Abstract #UEGW2020UEGW_5129;
N=249 --> 149 | Recruiting --> Active, not recruiting In the real-world, nal-IRI + 5-FU/LV is effective and well-tolerated in patients with metastatic pancreatic adenocarcinoma that progressed after gemcitabine-based therapy.
- Onivyde (nanoliposomal irinotecan) / Servier, Ipsen, Takeda, PharmaEngine
[VIRTUAL] NANOLIPOSOMAL IRINOTECAN WITH FLUOROURACIL AND FOLINIC ACID IN METASTATIC PANCREATIC CANCER AFTER PREVIOUS GEMCITABINE-BASED THERAPY: A REAL WORLD EXPERIENCE (Poster Exhibition) - Jul 19, 2020 - Abstract #UEGW2020UEGW_3153;
In the real-world, nal-IRI + 5-FU/LV is effective and well-tolerated in patients with metastatic pancreatic adenocarcinoma that progressed after gemcitabine-based therapy. In the real-world, nal-IRI + 5-FU/LV is effective and well-tolerated in patients with metastatic pancreatic adenocarcinoma that progressed after gemcitabine-based therapy.
- Onivyde (nanoliposomal irinotecan) / Servier, Ipsen, Takeda, PharmaEngine
[VIRTUAL] NANOLIPOSOMAL IRINOTECAN WITH FLUOROURACIL AND FOLINIC ACID IN METASTATIC PANCREATIC CANCER AFTER PREVIOUS GEMCITABINE-BASED THERAPY: A REAL WORLD EXPERIENCE (Poster Exhibition) - Jul 19, 2020 - Abstract #UEGW2020UEGW_1169;
In the real-world, nal-IRI + 5-FU/LV is effective and well-tolerated in patients with metastatic pancreatic adenocarcinoma that progressed after gemcitabine-based therapy. In the real-world, nal-IRI + 5-FU/LV is effective and well-tolerated in patients with metastatic pancreatic adenocarcinoma that progressed after gemcitabine-based therapy.
- || fluorouracil topical / Generic mfg., Avastin (bevacizumab) / Roche, irinotecan / Generic mfg.
Biomarker, Clinical, P2 data, Journal: MAVERICC, a randomized, biomarker-stratified, phase 2 study of mFOLFOX6-bevacizumab vs FOLFIRI-bevacizumab as first-line chemotherapy in metastatic colorectal cancer. (Pubmed Central) - Jul 18, 2020
P2
There were no new safety signals with these BV-containing regimens. ClinicalTrials.gov Identifier: NCT01374425.
- || leucovorin calcium / Generic mfg., fluorouracil / Generic mfg., irinotecan / Generic mfg.
Clinical, Journal: Synchronous Primary Pancreatic Ductal Carcinoma and Colonic Adenocarcinoma Present in a Patient With History of Skin Squamous Cell Carcinoma. (Pubmed Central) - Jul 15, 2020
The pathology diagnoses included moderately differentiated pancreatic ductal carcinoma (PDAC) with histiocyte-like features (tumor stage: ypT3N1M0) and moderately differentiated colonic adenocarcinoma, intestinal type (tumor stage: ypT3N0M0). To the best of our knowledge, this is the first documented case of synchronous primary colonic adenocarcinoma and PDAC in the English literature.
- | Trial completion date, Trial primary completion date: POWERRANGER: Preoperative Chemotherapy vs. Chemoradiation in Esophageal / GEJ Adenocarcinoma (clinicaltrials.gov) - Jul 14, 2020
P2/3, N=60, Recruiting, Sponsor: Dr. Gordon Buduhan
To the best of our knowledge, this is the first documented case of synchronous primary colonic adenocarcinoma and PDAC in the English literature. Trial completion date: Apr 2021 --> Jun 2022 | Trial primary completion date: Apr 2020 --> Jun 2021
- | Tomudex (raltitrexed) / Pfizer, AstraZeneca
Trial completion date, Trial termination: Compare Efficacy and Safety of Raltitrexed-based and 5fu-based Neoadjuvant Chemotherapy for Colorectal Liver Metastasis (clinicaltrials.gov) - Jul 14, 2020
P3, N=360, Terminated, Sponsor: Zhejiang University
Trial completion date: Apr 2021 --> Jun 2022 | Trial primary completion date: Apr 2020 --> Jun 2021 Trial completion date: Sep 2018 --> Sep 2019 | Recruiting --> Terminated; difficultly recruiting
- | Jelmyto (mitomycin urothelial gel) / UroGen
Trial initiation date: PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer (clinicaltrials.gov) - Jul 13, 2020
P1, N=16, Not yet recruiting, Sponsor: City of Hope Medical Center
Trial completion date: Sep 2018 --> Sep 2019 | Recruiting --> Terminated; difficultly recruiting Initiation date: Jun 2020 --> Sep 2020
- | New P2 trial: PASS-01: Pancreatic Adenocarcinoma Signature Stratification for Treatment (clinicaltrials.gov) - Jul 13, 2020
P2, N=150, Not yet recruiting, Sponsor: University Health Network, Toronto
- | Rubraca (rucaparib) / Pharma& Schweiz, Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
Trial completion date, Trial primary completion date, BRCA Biomarker, PARP Biomarker, Metastases: Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer (clinicaltrials.gov) - Jul 13, 2020
P2, N=110, Recruiting, Sponsor: Academic and Community Cancer Research United
Initiation date: Jun 2020 --> Sep 2020 Trial completion date: Nov 2021 --> Jul 2022 | Trial primary completion date: Nov 2020 --> Aug 2021
- ||| Imfinzi (durvalumab) / AstraZeneca, Koselugo (selumetinib) / Merck (MSD), AstraZeneca, Lynparza (olaparib) / Merck (MSD), AstraZeneca
Trial initiation date, BRCA Biomarker, PARP Biomarker, PD(L)-1 Biomarker, Metastases: MAZEPPA: Personalized Maintenance Therapy for m-PDAC Using Olaparib or Selumetinib + Durvalumab, Based on BRCAness and KRAS Status. (clinicaltrials.gov) - Jul 13, 2020
P2, N=307, Not yet recruiting, Sponsor: GERCOR - Multidisciplinary Oncology Cooperative Group
Trial completion date: Nov 2021 --> Jul 2022 | Trial primary completion date: Nov 2020 --> Aug 2021 Initiation date: May 2020 --> Aug 2020
- | leucovorin calcium / Generic mfg., fluorouracil / Generic mfg., irinotecan / Generic mfg.
Journal: Outcomes of Primary Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma. (Pubmed Central) - Jul 11, 2020
No pretreatment and posttreatment factors were associated with survival after pancreatectomy. This pragmatic observational cohort study with an intention-to-treat design provides real-world evidence of outcomes associated with the most current primary chemotherapy regimens used for borderline resectable and locally advanced pancreatic ductal adenocarcinoma.
- || fluorouracil topical / Generic mfg., Avastin (bevacizumab) / Roche, irinotecan / Generic mfg.
Biomarker, Clinical, P2 data, Journal: Phase II Randomized Trial of Sequential or Concurrent FOLFOXIRI-Bevacizumab Versus FOLFOX-Bevacizumab for Metastatic Colorectal Cancer (STEAM). (Pubmed Central) - Jul 10, 2020
P2
Alternating treatment of FOLFOX and FOLFIRI (sequential FOLFOXIRI-BEV) could improve tolerability. In the phase II STEAM trial, which is the largest study of FOLFOXIRI-BEV in patients in the U.S., it was found that both concurrent and sequential FOLFOXIRI-BEV are active and well tolerated in patients with previously untreated mCRC, supporting the use of these regimens as potential first-line treatment options for this population.
- ||| fluorouracil / Generic mfg., Avastin (bevacizumab) / Roche, irinotecan / Generic mfg.
Clinical, P3 data, Journal: Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial. (Pubmed Central) - Jul 10, 2020
P3
In the phase II STEAM trial, which is the largest study of FOLFOXIRI-BEV in patients in the U.S., it was found that both concurrent and sequential FOLFOXIRI-BEV are active and well tolerated in patients with previously untreated mCRC, supporting the use of these regimens as potential first-line treatment options for this population. Upfront FOLFOXIRI plus bevacizumab followed by the reintroduction of the same regimen after disease progression seems to be a preferable therapeutic strategy to sequential administration of chemotherapy doublets, in combination with bevacizumab, for patients with metastatic colorectal cancer selected according to the study criteria.
- ||| Enrollment open, Liquid biopsy, Biopsy: Post-surgical Liquid Biopsy-guided Treatment of Stage III and High-risk Stage II Colon Cancer Patients: the PEGASUS Trial (clinicaltrials.gov) - Jul 9, 2020
P2, N=140, Recruiting, Sponsor: IFOM, The FIRC Institute of Molecular Oncology
Upfront FOLFOXIRI plus bevacizumab followed by the reintroduction of the same regimen after disease progression seems to be a preferable therapeutic strategy to sequential administration of chemotherapy doublets, in combination with bevacizumab, for patients with metastatic colorectal cancer selected according to the study criteria. Not yet recruiting --> Recruiting
- || fluorouracil topical / Generic mfg., irinotecan / Generic mfg.
Clinical, Journal: Tumour response to TRK inhibition in a patient with pancreatic adenocarcinoma harbouring an NTRK gene fusion. (Pubmed Central) - Jul 9, 2020
P1/2, P2
However, acquired resistance to therapy can emerge in some patients. Next-generation TRK inhibitors such as LOXO-195 are currently in development to overcome this resistance (NCT02576431; NCT03215511).
- | Erbitux (cetuximab) / Eli Lilly
Trial completion date, Trial primary completion date: PARECEC: Perioperative Chemotherapy Plus Cetuximab Versus Chemotherapy Alone for High Risk Resectable Colorectal Liver Metastasis (clinicaltrials.gov) - Jul 9, 2020
P2/3, N=154, Recruiting, Sponsor: Beijing Cancer Hospital
Next-generation TRK inhibitors such as LOXO-195 are currently in development to overcome this resistance (NCT02576431; NCT03215511). Trial completion date: Dec 2018 --> Dec 2020 | Trial primary completion date: Sep 2018 --> Nov 2020
- | Enrollment closed, Enrollment change: GABLE: Postoperative Chemoradiation or Chemotherapy After Preoperative Chemotherapy for Gastric Cancers (clinicaltrials.gov) - Jul 9, 2020
P1, N=6, Active, not recruiting, Sponsor: Tannaz Armaghany
Trial completion date: Dec 2018 --> Dec 2020 | Trial primary completion date: Sep 2018 --> Nov 2020 Recruiting --> Active, not recruiting | N=40 --> 6
- || leucovorin calcium / Generic mfg., fluorouracil topical / Generic mfg.
Clinical, Journal: Induction Chemotherapy Reduces Patient-reported Toxicities During Neoadjuvant Chemoradiation with Intensity Modulated Radiotherapy for Rectal Cancer. (Pubmed Central) - Jul 7, 2020
This appears to be under-reported on clinician-reported assessments. Delivery of induction chemotherapy was associated with lower odds of experiencing urgency, bleeding, and tenesmus on PROs during subsequent CRT, with no significant impact on diarrhea and rectal pain.
- || fluorouracil / Generic mfg., Zaltrap (ziv-aflibercept IV) / Sanofi, Regeneron, irinotecan / Generic mfg.
Clinical, Journal, HEOR: Aflibercept Plus FOLFIRI for Second-line Treatment of Metastatic Colorectal Cancer: Observations from the Global Aflibercept Safety and Health-Related Quality-of-Life Program (ASQoP). (Pubmed Central) - Jul 7, 2020
P3
Delivery of induction chemotherapy was associated with lower odds of experiencing urgency, bleeding, and tenesmus on PROs during subsequent CRT, with no significant impact on diarrhea and rectal pain. The data from this study support the tolerability of the combination of aflibercept and FOLFIRI in a setting that more closely approximates real life in patients with mCRC who failed to respond to oxaliplatin-based chemotherapy, and also suggest an improvement in HRQL.
- || Clinical, Reimbursement, Journal, Medicare: Use of Bevacizumab for Elderly Patients With Stage IV Colon Cancer: Analysis of SEER-Medicare Data. (Pubmed Central) - Jul 7, 2020
Bevacizumab use has been slowly decreasing since 2005. Newer anti-epidermal growth factor receptor treatments have not been supplanting bevacizumab, as first-line biologic use in general has also decreased during this time period.
- ||| Clinical, P3 data, Journal: Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis (New EPOC): long-term results of a multicentre, randomised, controlled, phase 3 trial. (Pubmed Central) - Jul 7, 2020
Although the addition of cetuximab to chemotherapy improves the overall survival in some studies in patients with advanced, inoperable metastatic disease, its use in the perioperative setting in patients with operable disease confers a significant disadvantage in terms of overall survival. Cetuximab should not be used in this setting.
- | NN1213 / Novo Nordisk
Phase classification: NORMAL-R: Non-Operative Radiation Management of Adenocarcinoma of the Lower Rectum (clinicaltrials.gov) - Jul 7, 2020
P2, N=20, Completed, Sponsor: Washington University School of Medicine
Cetuximab should not be used in this setting. Phase classification: P1 --> P2
- | leucovorin calcium / Generic mfg., fluorouracil / Generic mfg.
Journal: Heme-Dependent ER Stress Apoptosis: A Mechanism for the Selective Toxicity of the Dihydroartemisinin, NSC735847, in Colorectal Cancer Cells. (Pubmed Central) - Jul 7, 2020
In addition, cell death was achieved at lower concentrations in colon cancer cells that were co-treated with folinic acid (Fol), 5-FU (F), and NSC735847 (FolFNSC), than Fol, F, and OX (FolFOX). The selective activity of NSC735847 and its ability to induce cytotoxicity at low concentrations suggest that NSC735847 may be an alternative for oxaliplatin in the FolFOX regimen for patients who are unable to tolerate its adverse effects.
- || Jemperli (dostarlimab-gxly) / GSK
Trial completion date, Trial primary completion date, Combination therapy, Metastases: CITRINO: Study of TSR-033 With an Anti-programmed Cell Death-1 Receptor (PD-1) in Participants With Advanced Solid Tumors (clinicaltrials.gov) - Jul 7, 2020
P1, N=55, Recruiting, Sponsor: Tesaro, Inc.
The selective activity of NSC735847 and its ability to induce cytotoxicity at low concentrations suggest that NSC735847 may be an alternative for oxaliplatin in the FolFOX regimen for patients who are unable to tolerate its adverse effects. Trial completion date: Feb 2021 --> Sep 2021 | Trial primary completion date: Feb 2021 --> Sep 2021
- | 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
Enrollment open: NOM-ERA: Non-Operative Management and Early Response Assessment in Rectal Cancer (clinicaltrials.gov) - Jul 7, 2020
P=N/A, N=68, Recruiting, Sponsor: Washington University School of Medicine
Trial completion date: Feb 2021 --> Sep 2021 | Trial primary completion date: Feb 2021 --> Sep 2021 Not yet recruiting --> Recruiting
- leucovorin calcium / Generic mfg., fluorouracil / Generic mfg.
[VIRTUAL] A Case of Fulminant Type 1 Diabetes Mellitus and Diabetic Ketoacidosis Caused by Adjuvant Chemotherapy for Colon Cancer (ATS 2020 Virtual) - Jul 6, 2020 - Abstract #ATSI2020ATS-I_5556;
We report a rare complication of FOLFOX in which a patient developed severe DKA due to FT1D. Further studies are needed to investigate the underlying mechanism.
- leucovorin calcium / Generic mfg., doxorubicin hydrochloride / Generic mfg., cyclophosphamide intravenous / Generic mfg.
[VIRTUAL] A Rare Case of Primary Cardiac Burkitt Lymphoma (ATS 2020 Virtual) - Jul 6, 2020 - Abstract #ATSI2020ATS-I_4282;
Treatment consists of a mixture of surgery, chemotherapy, radiation, and stem cell transplantation. Expedient debulking and initiation of chemotherapy is imperative, as Burkitt lymphoma is rapidly progressive and obstructing intracardiac masses can cause hemodynamic compromise.
- leucovorin calcium / Generic mfg.
[VIRTUAL] A Case of CNS Iris in a Patient with AIDS (ATS 2020 Virtual) - Jul 6, 2020 - Abstract #ATSI2020ATS-I_4097;
Toxoplasma-associated CNS IRIS can show worsening of MRI scans even as T. gondii parasite loads decrease. The treatment is focused on reducing cerebral edema, and treatment of the underlying infection.
- | New P3 trial: Chemoradiotherapy Followed by Planned Surgery or by Surveillance and Surgery Only When Needed for Oesophageal Cancer (clinicaltrials.gov) - Jul 6, 2020
P3, N=1000, Not yet recruiting, Sponsor: Karolinska University Hospital
- | Journal, Next-Generation Sequencing: Afatinib treatment for her-2 amplified metastatic colorectal cancer based on patient-derived xenograft models and next generation sequencing. (Pubmed Central) - Jul 4, 2020
The treatment is focused on reducing cerebral edema, and treatment of the underlying infection. NGS and PDX models have great significance for precision and individualized medicine in the mCRC treatment, especially for patients whose diseases have been progressed after multiline standard therapies.
- || dexamethasone / Generic mfg., vincristine / Generic mfg.
Clinical, Journal: Excellent long-term survival of children with Down syndrome and standard-risk ALL: a report from the Children's Oncology Group. (Pubmed Central) - Jul 4, 2020
P3
This trial demonstrated that 5 doses of vincristine and escalating IV methotrexate (MTX) without leucovorin rescue in the interim maintenance (IM) phases resulted in superior event-free survival (EFS) when compared with 2 doses of vincristine, oral (PO) MTX, PO mercaptopurine, and dexamethasone...The incidence of mucositis was increased in patients with DS as compared with patients without DS, particularly among patients who received IV MTX. This trial was registered at www.clinicaltrials.gov as #NCT00005945.
- | leucovorin calcium / Generic mfg., methotrexate / Generic mfg.
Journal: Methotrexate significantly induces apoptosis by inhibiting STAT3 activation in NPM-ALK-positive ALCL cells. (Pubmed Central) - Jul 4, 2020
Methotrexate significantly induced apoptosis in ALK inhibitor-resistant cells expressing the NPM-ALK mutant harboring the point mutation, G262R, and in ALCL patient-derived NPM-ALK-positive Ki-JK cells. Collectively, these results demonstrate the potential therapeutic application of methotrexate, which inhibits the activation of STAT3, to NPM-ALK-positive ALCL.
- | leucovorin calcium / Generic mfg., fluorouracil / Generic mfg., irinotecan / Generic mfg.
Journal: Nationwide trends in incidence, treatment and survival of pancreatic ductal adenocarcinoma. (Pubmed Central) - Jul 4, 2020
Resection rates and use of adjuvant or palliative chemotherapy increased with improved survival in these patients. In all patients with PDAC, however, the survival benefit of 3 weeks is negligible because the majority of patients only received supportive care.
- | leucovorin calcium / Generic mfg.
Journal: Comparison of treatment for low-risk GTN with standard 8-day MTX/FA regimen versus modified MTX/FA regimen without chemotherapy on the weekend. (Pubmed Central) - Jul 3, 2020
The modified 8-day MTX/FA regimen didn't compromise oncologic outcomes for women with low-risk GTN. This regimen appears to be an acceptable alternative to standard 8-day MTX/FA when treatment on weekend isn't an option.
- leucovorin calcium / Generic mfg., methotrexate / Generic mfg., cyclophosphamide intravenous / Generic mfg.
[VIRTUAL] DELAYED ENGRAFTMENT AND PROLONGED HOSPITAL STAY FOLLOWING OMISSION OF FOLINIC ACID AFTER METHOTREXATE FOR GVHD PROPHYLAXIS IN ALLOGENEIC TRANSPLANT RECIPIENTS (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_4540;
We postulate that despite low plasma MTX levels at time of administration, folinic acid rescue ameliorates MTX-induced suppression of neutrophil recovery. Based on these results our programme has returned to routine folinic acid rescue after MTX.
- leucovorin calcium / Generic mfg., methotrexate / Generic mfg., cyclophosphamide intravenous / Generic mfg.
[VIRTUAL] DELAYED ENGRAFTMENT AND PROLONGED HOSPITAL STAY FOLLOWING OMISSION OF FOLINIC ACID AFTER METHOTREXATE FOR GVHD PROPHYLAXIS IN ALLOGENEIC TRANSPLANT RECIPIENTS (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_4539;
We postulate that despite low plasma MTX levels at time of administration, folinic acid rescue ameliorates MTX-induced suppression of neutrophil recovery. Based on these results our programme has returned to routine folinic acid rescue after MTX.
- leucovorin calcium / Generic mfg., methotrexate / Generic mfg., cyclophosphamide intravenous / Generic mfg.
[VIRTUAL] DELAYED ENGRAFTMENT AND PROLONGED HOSPITAL STAY FOLLOWING OMISSION OF FOLINIC ACID AFTER METHOTREXATE FOR GVHD PROPHYLAXIS IN ALLOGENEIC TRANSPLANT RECIPIENTS (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_4538;
We postulate that despite low plasma MTX levels at time of administration, folinic acid rescue ameliorates MTX-induced suppression of neutrophil recovery. Based on these results our programme has returned to routine folinic acid rescue after MTX.
- leucovorin calcium / Generic mfg.
[VIRTUAL] SURVEILLANCE FOR REACTIVATION OF TOXOPLASMA GONDII USING POLYMERASE CHAIN REACTION ASSAY AND PRE-EMPTIVE THERAPY AVOIDS UNIVERSAL PROPHYLAXIS AND PREVENTS SYMPTOMATIC INFECTION (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_3856;
Prompt treatment was effective in all cases with a return to PCR negativity. No patients developed symptoms.
- leucovorin calcium / Generic mfg.
[VIRTUAL] SURVEILLANCE FOR REACTIVATION OF TOXOPLASMA GONDII USING POLYMERASE CHAIN REACTION ASSAY AND PRE-EMPTIVE THERAPY AVOIDS UNIVERSAL PROPHYLAXIS AND PREVENTS SYMPTOMATIC INFECTION (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_3855;
Prompt treatment was effective in all cases with a return to PCR negativity. No patients developed symptoms.
- leucovorin calcium / Generic mfg.
[VIRTUAL] SURVEILLANCE FOR REACTIVATION OF TOXOPLASMA GONDII USING POLYMERASE CHAIN REACTION ASSAY AND PRE-EMPTIVE THERAPY AVOIDS UNIVERSAL PROPHYLAXIS AND PREVENTS SYMPTOMATIC INFECTION (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_3854;
Prompt treatment was effective in all cases with a return to PCR negativity. No patients developed symptoms.
- | leucovorin calcium / Generic mfg., methotrexate / Generic mfg.
Journal: Development of an algorithm to detect methotrexate wrong frequency error using computerized health care data. (Pubmed Central) - Jul 2, 2020
Rescue therapy is a specific indicator of methotrexate overdose among first methotrexate dispensings. This method is generalizable to other medications with serious adverse events treated with antidotes.
- || leucovorin calcium / Generic mfg., fluorouracil / Generic mfg.
Clinical, Journal: Dose-finding study of modified FLOT (mFLOT) regimen as first-line treatment in Chinese patients with metastatic adenocarcinoma of stomach. (Pubmed Central) - Jul 2, 2020
The RD of modified FLOT regimen in Chinese patients with advanced gastric cancer was docetaxel 45 mg/m, oxaliplatin 75 mg/m, leucovorin 200 mg/m and fluorouracil 2200 mg/m on day 1 of every 14-day cycle. Its efficacy will be assessed by further phase II study.
- ||||| bemarituzumab (AMG 552) / Amgen
Enrollment closed, Metastases: FIGHT: A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer (clinicaltrials.gov) - Jul 2, 2020
P3, N=548, Active, not recruiting, Sponsor: Five Prime Therapeutics, Inc.
Its efficacy will be assessed by further phase II study. Recruiting --> Active, not recruiting
- || Herceptin (trastuzumab) / Roche, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment closed: INTEGA: Ipilimumab or FOLFOX in Combination With Nivolumab and Trastuzumab in HER2 Positive EsophagoGastric Adenocarcinoma (clinicaltrials.gov) - Jun 30, 2020
P2, N=97, Active, not recruiting, Sponsor: AIO-Studien-gGmbH
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | Trial completion date, Trial primary completion date: Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial (clinicaltrials.gov) - Jun 29, 2020
P1, N=40, Recruiting, Sponsor: OHSU Knight Cancer Institute
Recruiting --> Active, not recruiting Trial completion date: Feb 2021 --> Feb 2025 | Trial primary completion date: Feb 2021 --> Feb 2022
- | New P2 trial, Surgery: PANCREAS: Pancreatic Adenocarcinoma Neoadjuvant Chemotherapy Before Surgery (clinicaltrials.gov) - Jun 29, 2020
P2, N=30, Not yet recruiting, Sponsor: Hamilton Health Sciences Corporation
- | Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment open, Enrollment change, IO biomarker: AIO-STO-0417: Modified FOLFOX Plus/Minus Nivolumab and Ipilimumab vs. FLOT Plus Nivolumab in Patients With Previously Untreated Advanced or Metastatic Gastric Cancer (clinicaltrials.gov) - Jun 28, 2020
P2, N=207, Recruiting, Sponsor: Institut f
Trial completion date: Feb 2021 --> Feb 2025 | Trial primary completion date: Feb 2021 --> Feb 2022 Active, not recruiting --> Recruiting | N=119 --> 207